Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
clinical trial
curative treatment
elderly patients
geriatric oncology
prostate cancer
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
medline:
12
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
aheadofprint
Résumé
Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs life and improves health-related quality of life (HRQoL) in this age group compared to conservative therapy, which has evolved considerably during the last decade. The Scandinavian Prostate Cancer Group (SPCG) 19/Norwegian Get-Randomized Research Group-Prostate (GRand-P) is a randomised, two-armed, controlled, multicentre, phase III trial carried out at study centres in Norway, Denmark, Finland, and Sweden. The primary endpoints are overall survival and HRQoL (burden of disease scale, European Organisation for the Research and Treatment of Cancer [EORTC] Elderly Cancer patients). Secondary endpoints are PCa-specific survival, metastasis-free survival, role-functioning scale (EORTC quality of life questionnaire 30-item core), urinary irritative/obstructive scale (26-item Expanded Prostate Cancer Index Composite [EPIC-26]), bowel scale (EPIC-26), intervention-free survival, PCa morbidity, use of secondary and tertiary systemic therapies, mean quality-adjusted life-years (QALYs), and mean total healthcare costs. A total of 980 men (aged ≥75 years) with non-metastatic, high-risk PCa will initially be screened with Geriatric 8 (G8) health status screening tool and Mini-COG© brief cognitive test. Participants identified by G8 as 'fit' or 'frail' will be randomised (ratio 1:1) to either immediate curative therapy (radiotherapy or prostatectomy) or conservative therapy (endocrine therapy or observation). Participants who are unable or unwilling to participate in randomisation will be enrolled in a separate observation group. Randomised patients will be followed for 10 years. Ethics approval has been granted in Norway (457593), Denmark (H-22051998), Finland (R23043) and Sweden (Dnr 2023-05296-01). The trial is registered on Clinicaltrials.org (NCT05448547).
Sections du résumé
BACKGROUND
BACKGROUND
Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs life and improves health-related quality of life (HRQoL) in this age group compared to conservative therapy, which has evolved considerably during the last decade.
STUDY DESIGN
METHODS
The Scandinavian Prostate Cancer Group (SPCG) 19/Norwegian Get-Randomized Research Group-Prostate (GRand-P) is a randomised, two-armed, controlled, multicentre, phase III trial carried out at study centres in Norway, Denmark, Finland, and Sweden.
ENDPOINTS
METHODS
The primary endpoints are overall survival and HRQoL (burden of disease scale, European Organisation for the Research and Treatment of Cancer [EORTC] Elderly Cancer patients). Secondary endpoints are PCa-specific survival, metastasis-free survival, role-functioning scale (EORTC quality of life questionnaire 30-item core), urinary irritative/obstructive scale (26-item Expanded Prostate Cancer Index Composite [EPIC-26]), bowel scale (EPIC-26), intervention-free survival, PCa morbidity, use of secondary and tertiary systemic therapies, mean quality-adjusted life-years (QALYs), and mean total healthcare costs.
PATIENTS AND METHODS
METHODS
A total of 980 men (aged ≥75 years) with non-metastatic, high-risk PCa will initially be screened with Geriatric 8 (G8) health status screening tool and Mini-COG© brief cognitive test. Participants identified by G8 as 'fit' or 'frail' will be randomised (ratio 1:1) to either immediate curative therapy (radiotherapy or prostatectomy) or conservative therapy (endocrine therapy or observation). Participants who are unable or unwilling to participate in randomisation will be enrolled in a separate observation group. Randomised patients will be followed for 10 years.
TRIAL REGISTRATION
BACKGROUND
Ethics approval has been granted in Norway (457593), Denmark (H-22051998), Finland (R23043) and Sweden (Dnr 2023-05296-01). The trial is registered on Clinicaltrials.org (NCT05448547).
Banques de données
ClinicalTrials.gov
['NCT05448547']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Nordic Cancer Union
Organisme : KLINBEFORSK
Organisme : Helse Sør-Øst RHF
Organisme : Kreftforeningen
Informations de copyright
© 2024 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Références
Aas K, Dorothea Fosså S, Åge Myklebust T et al. Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study. Cancer Med 2020; 9: 6646-6657
Löffeler S, Halland A, Fawad H, Beisland C, Haug ES. Non-metastatic prostate cancer: rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly. Scand J Urol 2020; 54: 105-109
Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol 2011; 60: 554-563
Årsrapport 2022 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for prostatakreft. Oslo: Kreftregisteret, 2023
Loffeler S, Halland A, Weedon-Fekjaer H, Nikitenko A, Ellingsen CL, Haug ES. High Norwegian prostate cancer mortality: evidence of over-reporting. Scand J Urol 2018; 52: 122-128
Richstone L, Bianco FJ, Shah HH et al. Radical prostatectomy in men aged > or =70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int 2008; 101: 541-546
Brassell SA, Rice KR, Parker PM et al. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. J Urol 2011; 185: 132-137
Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012; 118: 3062-3070
Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011; 29: 235-241
Bratt O, Folkvaljon Y, Hjalm Eriksson M et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol 2015; 68: 53-58
Yang DD, Mahal BA, Muralidhar V et al. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer 2017; 123: 4832-4840
Årsrapport 2019 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for prostatakreft. Oslo: Kreftregisteret (Norwegian Cancer Registry), 2020
Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol 2018; 29: 377-385
Bratt O, Carlsson S, Fransson P, Stranne J, Kindblom J. The Swedish national guidelines on prostate cancer, part I: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol 2022; 56: 265-273
Bill-Axelson A, Holmberg L, Garmo H et al. Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up. N Engl J Med 2018; 379: 2319-2329
Fosså SD, Wiklund F, Klepp O et al. Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of The Scandinavian Prostate Cancer Group-7. Eur Urol 2016; 70: 684-691
Mulders PF, Molina A, Marberger M et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 2014; 65: 875-883
Feng Z, Graff JN. Next-generation androgen receptor-signaling inhibitors for prostate cancer: considerations for older patients. Drugs Aging 2021; 38: 111-123
Hofman CS, Makai P, Boter H et al. The influence of age on health valuations: the older olds prefer functional independence while the younger olds prefer less morbidity. Clin Interv Aging 2015; 10: 1131-1139
Wedding U, Pientka L, Höffken K. Quality-of-life in elderly patients with cancer: a short review. Eur J Cancer 2007; 43: 2203-2210
Seghers P, Wiersma A, Festen S et al. Patient preferences for treatment outcomes in oncology with a focus on the older patient-a systematic review. Cancer 2022; 14: 1147
Cherny NI, Dafni U, Bogaerts J et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol 2017; 28: 2340-2366
Hamdy FC, Donovan JL, Lane JA et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023; 388: 1547-1558
Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213
Mason MD, Parulekar WR, Sydes MR et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 2015; 33: 2143-2150
Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-1073
Droz JP, Albrand G, Gillessen S et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol 2017; 72: 521-531
Attard G, Murphy L, Clarke NW et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022; 399: 447-460
Aghdam N, Pepin A, Carrasquilla M et al. Self-reported burden in elderly patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT). Front Oncol 2019; 9: 1528
Hamdy FC, Donovan JL, Lane JA et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415-1424
Warde P, Mason M, Ding K et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-2111
Pang HH, Wang X, Stinchcombe TE et al. Enrollment trends and disparity among patients with lung cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol 2016; 34: 3992-3999
Sammon JD, Abdollah F, D'Amico A et al. Predicting life expectancy in men diagnosed with prostate cancer. Eur Urol 2015; 68: 756-765
Wilson JR, Clarke MG, Ewings P, Graham JD, MacDonagh R. The assessment of patient life-expectancy: how accurate are urologists and oncologists? BJU Int 2005; 95: 794-798
Sheng W, Kirschner-Hermanns R, Zhang H. Elderly patients aged >/= 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis. World J Urol 2018; 37: 317-325
Vatandoust S, Kichenadasse G, O'Callaghan M et al. Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry. BJU Int 2018; 121(Suppl 3): 48-54
Attard G, Parker C, Eeles RA et al. Prostate cancer. Lancet 2016; 387: 70-82
Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of patient-reported outcomes in routine medical care. Am Soc Clin Oncol Educ Book 2018; 38: 122-134
Mierzynska J, Piccinin C, Pe M et al. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. Lancet Oncol 2019; 20: e685-e698
Scotté F, Bossi P, Carola E et al. Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide. Ann Oncol 2018; 29: 1718-1726
Droz JP, Balducci L, Bolla M et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010; 106: 462-469
Cornford P, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017; 71: 630-642
Mottet N, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-629